Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Innovative Bone Marrow CAR-T Cell Manufacturing for AML: Enhancing Viability and Tumor Migration

Jose Antonio Bejarano Garcia, Daniel Primo, Maria Jose Palacios Barea, Belén Sierro, Beatriz Guijarro-Albaladejo, Xian Weng, Miranda Omenaca, Estefania Garcia-Guerrero, Joan Ballesteros, Jose Antonio Pérez-Simón

Blood (2024) 144 (Supplement 1): 3478.

https://doi.org/10.1182/blood-2024-201457

Published: 2024

Journal Articles

Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 7400–7401.

https://doi.org/10.1182/blood-2022-157199

Published: 2022

Journal Articles

Clinical Correlation of a Precision Medicine Test with Treatment Outcome in Acute Myeloid Leukemia Patients

Hong-Hu Zhu, MD, Min Ji, MD, Chunyan Ji, MD, Chongwu Wang, Yaqiong Ge, Xiaoping Zhou, Julian Gorrochategui, Daniel Primo, PhD, Joan Ballesteros, PhD, Li Li, MD, Joaquin Martinez-López

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-140252

Published: 2020

Journal Articles

Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates

Joaquin Martinez-Lopez, MD PhD, Pau Montesinos, MD PhD, Pilar Martinez Sanchez, Julian Gorrochategui, Jose Luis Rojas, Daniel Primo, PhD, Juan-Miguel Bergua, MD, Rosa M M. Ayala, MD PhD, Maria Calbacho, MD, Nieves López-Muñoz, Evelyn Acuña, MD, Jose Antonio Pérez-Simón, MD, Adolfo de la Fuente, Jaime Perez De Oteyza, MDPhD, Rebeca Rodríguez-Veiga, MD, Blanca Boluda, Isabel Cano, MD, Joan Ballesteros, PhD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-134336

Published: 2020

Journal Articles

NKG2D CAR-Expressing Lymphocytes Target Acute Myeloid Leukemia Cells

Alejandra Leivas, PhD BS, MSc, Laura Córdoba, MSc, Antonio Valeri, PhD, Paula Rio, PhD, Daniel Primo, PhD, Joan Ballesteros, PhD, Lucía Fernández, PhD, Antonio Perez-Martinez, MD PhD, Dean Anthony Lee, MD PhD, Daniel J. Powell, Jr., PhD, Joaquin Martinez-Lopez, MD PhD

Blood (2019) 134 (Supplement_1): 2667.

https://doi.org/10.1182/blood-2019-123371

Published: 2019

Journal Articles

Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments

Blood (2018) 132 (Supplement 1): 1493.

https://doi.org/10.1182/blood-2018-99-115849

Published: 2018

Journal Articles

Bispecific Antibodies on Hematological Malignancies: A Novel Mechanism of Action That May Contribute to Therapeutic Efficacy

Daniel Primo, PhD, Pilar Hernandez, Javier de la Serna, MD, Josep-Maria Ribera, MD, Susana Vives, MD, Juan Bergua, MD, Jaime Perez de Oteyza, MD, Josefina Serrano, MD, Julian Gorrochategui, Vicente María Luisa, David Martínez-Cuadron, MD, Pau Montesinos, MD PhD, Joaquin Martinez Lopez, MD PhD, Joan Ballesteros, PhD

Blood (2017) 130 (Supplement 1): 2289.

https://doi.org/10.1182/blood.V130.Suppl_1.2289.2289

Published: 2017

Journal Articles

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

Michael P Rettig, PhD, John Godwin, MD, Norbert Vey, Bernard Fox, PhD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Daner Li, MS, Daniel Primo, PhD, Joan Ballesteros, PhD, Jichao Sun, PhD, Helene Lelièvre, PhD PharmD, Jan Baughman, MPH, Ross La Motte-Mohs, PhD, John Muth, MS, Paul Moore, PhD, Ezio Bonvini, MD, Jon Wigginton, John F DiPersio, MD PhD, Jan Davidson-Moncada, MDPhD

Blood (2017) 130 (Supplement 1): 1365.

https://doi.org/10.1182/blood.V130.Suppl_1.1365.1365

Published: 2017

Journal Articles

An Innovative High-Throughput Ex Vivo Drug Assay Incorporating the Native Microenvironment Reveals a Novel Mechanism of Action of Idelalisib in CLL

Joan Ballesteros, Lydia Scarfo, Mattias Mattsson, Aliki Xochelli, Pamela Ranghetti, Daniel Primo, Alicia Robles, Julian Gorrochategui, Joaquin Martinez-Lopez, Javier De la Serna, Marcos González, MD PhD, Veerendra Munugalavadla, Richard Rosenquist, Kostas Stamatopoulos, Christophe Quéva, PhD, Paolo Ghia, MD PhD

Blood (2015) 126 (23): 2485.

https://doi.org/10.1182/blood.V126.23.2485.2485

Published: 2015

Journal Articles

The Alkylating Histone Deacetylase Inhibitor Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological Malignancies

Ana Alicia López-Iglesias, MD, Laura San-Segundo, Lorena González-Méndez, Susana Hernández-García, Daniel Primo, PhD, Mercedes Garayoa, PhD BS, Ana Belén Hernández, PhD, Teresa Paíno, PhD, Maria-Victoria Mateos, MD PhD, Yi Chen, Enrique M. Ocio, MD PhD, Thomas Mehrling, MD PhD

Blood (2014) 124 (21): 2100.

https://doi.org/10.1182/blood.V124.21.2100.2100

Published: 2014

Journal Articles

Development of a High-Throughput Screening Assay with Nurse-like Cell-Based Microenviroment in Chronic Lymphoid Leukemia Cells.

Blood (2014) 124 (21): 3639.

https://doi.org/10.1182/blood.V124.21.3639.3639

Published: 2014

Journal Articles

Ruxolitinib in Combination with Nilotinib and Prednisolone, a New Synergistic Approach to Treat Myelofibrosis

Alicia Arenas, Pilar Hernandez-Campo, PhD, Julian Gorrochategui, Daniel Primo, PhD, Rosa M. Ayala, MD PhD, Blanca Ferrer-Lores, MD, Joan Ballesteros, PhD, Joaquin Martinez-Lopez, MD PhD

Blood (2014) 124 (21): 903.

https://doi.org/10.1182/blood.V124.21.903.903

Published: 2014

Journal Articles

Novel Ex Vivo Assay Measures Drug-Induced Depletion of Hematopoietic Progenitors As an Estimate of Hematotoxicity

Blood (2014) 124 (21): 5785.

https://doi.org/10.1182/blood.V124.21.5785.5785

Published: 2014

Journal Articles

High Throughput Screening, With a Flow Cytometry Automated Platform (Ex vivo Biotech), To Identify Potential Combination Partners, For The JAK 2 Inhibitor Ruxolitinib

Alicia Arenas, Pilar Hernandez-Campo, Daniel Primo, Santiago Barrio, PhD, Rosa M. Ayala, MD, PhD, Joan Ballesteros, Joaquín Martínez-López, MD, PhD

Blood (2013) 122 (21): 2534.

https://doi.org/10.1182/blood.V122.21.2534.2534

Published: 2013

Journal Articles

Pharmacological Profile Of Cytarabine and Idarubicin In Patient Samples (ex vivo) With Newly Diagnosed Acute Myeloid Leukemia Identifies Responders Vs Non Responders

Blood (2013) 122 (21): 3923.

https://doi.org/10.1182/blood.V122.21.3923.3923

Published: 2013

Journal Articles

Personalizing Therapies With Ex Vivo Pharmacological Responses May Uncover The Differences Between IDA-DNR-MIT Among European AML Protocols

Blood (2013) 122 (21): 1294.

https://doi.org/10.1182/blood.V122.21.1294.1294

Published: 2013

Journal Articles

Population Pharmacological Profiles Of AML Treatments In Patient Samples By Automated Flow Cytometry; A Bridge To Individualized Medicine

Blood (2013) 122 (21): 1347.

https://doi.org/10.1182/blood.V122.21.1347.1347

Published: 2013

Journal Articles

BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The Eμ-TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent Of TP53 Mutation Status

Connie A Larsson, Kensuke Kojima, MD, PhD, Yong Wang, PhD, Nicholas Navin, PhD, Miguel Gallardo, PhD, Daniel Primo, Jose L. Rojas, Joaquin Martinez, Taghi Manshouri, Ph.D., Hun Ju Lee, MD, James E Bradner, MD, Juan Ballesteros, Sean M. Post, PhD, Guillermina (Gigi) Lozano, PhD, Alfonso Quintás-Cardama, MD

Blood (2013) 122 (21): 876.

https://doi.org/10.1182/blood.V122.21.876.876

Published: 2013

Journal Articles

Personalized Medicine Test of Multi-Drug Protocols Ex Vivo for Hematological Malignancies.

Blood (2009) 114 (22): 2655.

https://doi.org/10.1182/blood.V114.22.2655.2655

Published: 2009

Journal Articles

Screening Thousands of Drugs in Leukemia Patient Samples to Identify Novel Uses for Approved Drugs.

Blood (2009) 114 (22): 4414.

https://doi.org/10.1182/blood.V114.22.4414.4414

Published: 2009

NARROW

Innovative Bone Marrow CAR-T Cell Manufacturing for AML: Enhancing Viability and Tumor Migration

Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Clinical Correlation of a Precision Medicine Test with Treatment Outcome in Acute Myeloid Leukemia Patients

Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates

NKG2D CAR-Expressing Lymphocytes Target Acute Myeloid Leukemia Cells

Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments

Bispecific Antibodies on Hematological Malignancies: A Novel Mechanism of Action That May Contribute to Therapeutic Efficacy

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

An Innovative High-Throughput Ex Vivo Drug Assay Incorporating the Native Microenvironment Reveals a Novel Mechanism of Action of Idelalisib in CLL

The Alkylating Histone Deacetylase Inhibitor Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological Malignancies

Development of a High-Throughput Screening Assay with Nurse-like Cell-Based Microenviroment in Chronic Lymphoid Leukemia Cells.

Ruxolitinib in Combination with Nilotinib and Prednisolone, a New Synergistic Approach to Treat Myelofibrosis

Novel Ex Vivo Assay Measures Drug-Induced Depletion of Hematopoietic Progenitors As an Estimate of Hematotoxicity

High Throughput Screening, With a Flow Cytometry Automated Platform (Ex vivo Biotech), To Identify Potential Combination Partners, For The JAK 2 Inhibitor Ruxolitinib

Pharmacological Profile Of Cytarabine and Idarubicin In Patient Samples (ex vivo) With Newly Diagnosed Acute Myeloid Leukemia Identifies Responders Vs Non Responders

Personalizing Therapies With Ex Vivo Pharmacological Responses May Uncover The Differences Between IDA-DNR-MIT Among European AML Protocols

Population Pharmacological Profiles Of AML Treatments In Patient Samples By Automated Flow Cytometry; A Bridge To Individualized Medicine

BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The Eμ-TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent Of TP53 Mutation Status

Personalized Medicine Test of Multi-Drug Protocols Ex Vivo for Hematological Malignancies.

Screening Thousands of Drugs in Leukemia Patient Samples to Identify Novel Uses for Approved Drugs.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only